arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Valion Bio, Inc.

VBIO
$0.28 ▲ +0.02 (+6.53%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
22 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
16
Health
Poor
Bearish
auto_awesome

Analytical Summary

Valion Bio, Inc. faces fundamental challenges. The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -40.2%
FCF / Share $-1.74
Trailing P/E
Price / Book 0.1x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

22-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$146.00K
↑ +15.9%
Net Income Profit after all expenses
$-6.20M
↓ -312.9%
Operating Margin Operating profit as % of sales
-443.4%
— +0.1%
FCF / Share Free cash flow per share
$-1.74
↓ -16.7%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
1
Cash Quality
53

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 6 years · 22 quarters